Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

NCT: NCT05092516 · ACTIVE_NOT_RECRUITING

NCT IDNCT05092516
StatusACTIVE_NOT_RECRUITING
Start Date2022-06-07
Completion2026-06-15

Brief Summary

The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.

Frequently Asked Questions

What is Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)?

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC) is a clinical trial registered under NCT05092516. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05092516?

The current status of NCT05092516 (Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)) is: ACTIVE_NOT_RECRUITING.

When did Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC) start?

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC) started on 2022-06-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑